ASX - Delayed Quote • AUD
CSL Limited (CSL.AX)
At close: April 26 at 4:10 PM GMT+10
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
14,035,200.00
13,174,000.00
10,493,100.00
10,265,300.00
9,100,500.00
Cost of Revenue
6,867,700.00
6,466,000.00
4,829,600.00
4,466,700.00
3,924,400.00
Gross Profit
7,167,500.00
6,708,000.00
5,663,500.00
5,798,600.00
5,176,100.00
Operating Expense
4,642,600.00
4,606,000.00
3,347,400.00
3,208,600.00
2,929,700.00
Operating Income
2,524,900.00
2,102,000.00
2,316,100.00
2,590,000.00
2,246,400.00
Net Non Operating Interest Income Expense
-469,000.00
-406,000.00
-160,600.00
-166,900.00
-143,800.00
Other Income Expense
144,300.00
136,000.00
81,600.00
44,700.00
50,300.00
Pretax Income
3,078,700.00
2,663,000.00
2,779,600.00
2,963,100.00
2,572,700.00
Tax Provision
554,900.00
419,000.00
524,900.00
588,100.00
470,200.00
Net Income Common Stockholders
2,471,800.00
2,194,000.00
2,254,700.00
2,375,000.00
2,102,500.00
Basic EPS
5.12
4.55
4.81
5.22
4.63
Diluted EPS
5.09
4.53
4.80
5.21
4.62
Basic Average Shares
482,568.98
482,173.15
468,754.86
454,865.60
453,808.10
Diluted Average Shares
485,253.58
484,326.71
469,729.17
455,854.13
455,579.63
Net Income from Continuing & Discontinued Operation
2,471,800.00
2,194,000.00
2,254,700.00
2,375,000.00
2,102,500.00
Normalized Income
2,471,800.00
2,194,000.00
2,254,700.00
2,375,000.00
2,102,500.00
Interest Income
23,300.00
38,000.00
17,400.00
3,900.00
7,000.00
Interest Expense
428,300.00
408,000.00
142,800.00
170,800.00
150,800.00
Net Interest Income
-469,000.00
-406,000.00
-160,600.00
-166,900.00
-143,800.00
EBIT
3,507,000.00
3,071,000.00
2,922,400.00
3,133,900.00
2,723,500.00
EBITDA
4,385,500.00
3,902,000.00
3,464,900.00
3,629,200.00
3,143,300.00
Reconciled Cost of Revenue
6,867,700.00
6,466,000.00
4,829,600.00
4,466,700.00
3,924,400.00
Reconciled Depreciation
878,500.00
831,000.00
542,500.00
495,300.00
419,800.00
Net Income from Continuing Operation Net Minority Interest
2,471,800.00
2,194,000.00
2,254,700.00
2,375,000.00
2,102,500.00
Normalized EBITDA
4,385,500.00
3,902,000.00
3,464,900.00
3,629,200.00
3,143,300.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
6/30/2020 - 5/31/1994
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TLX.AX Telix Pharmaceuticals Limited
14.91
+0.20%
MSB.AX Mesoblast Limited
0.9300
+1.64%
NEU.AX Neuren Pharmaceuticals Limited
18.65
-1.06%
IMM.AX Immutep Limited
0.4200
-6.67%
CUV.AX Clinuvel Pharmaceuticals Limited
14.57
-2.80%
IMU.AX Imugene Limited
0.0790
-4.82%
PAA.AX PharmAust Limited
0.2400
-4.00%
DXB.AX Dimerix Limited
0.3200
-4.48%
PYC.AX PYC Therapeutics Limited
0.0920
-1.08%
SPL.AX Starpharma Holdings Limited
0.1350
0.00%